Assessing the Anti-Inflammatory Activity of the Anxiolytic Drug Buspirone Using CRISPR-Cas9 Gene Editing in LPS-Stimulated BV-2 Microglial Cells

Assessing the Anti-Inflammatory Activity of the Anxiolytic Drug Buspirone Using CRISPR-Cas9 Gene Editing in LPS-Stimulated BV-2 Microglial Cells

Buspirone is an anxiolytic drug with robust serotonin receptor 1A (Htr1a) agonist activities. However, evidence has demonstrated that this drug also targets the dopamine D3 receptor (Drd3), where it acts as a potent antagonist. In vivo, Drd3 blockade is neuroprotective and reduces inflammation in mo...

Full description

Bibliographic Details
Main Authors: Sarah Thomas Broome, Teagan Fisher, Alen Faiz, Kevin A. Keay, Giuseppe Musumeci, Ghaith Al-Badri, Alessandro Castorina
Format: Article
Language:English
Published: MDPI AG 2021-05-01
Series:Cells
Subjects:
microglia
dopamine D3 receptor
5-hydroxytryptamine 1a receptor
neuroinflammation
Parkinson’s disease
Online Access:https://www.mdpi.com/2073-4409/10/6/1312

Internet

https://www.mdpi.com/2073-4409/10/6/1312

Similar Items